Glodom's 2024 Annual Meeting, themed "The Golden Snake Soars, and Wisdom Usher in a New Journey", was successfully held on January 18, 2025. With branches connected online, employees shared a wonderful time. It featured speeches, video reviews, performances, lucky draws, and award - giving sessions, followed by offline activities and a dinner, strengthening the company's cohesion and looking forward to the future development.
This article explores the impact of outstanding game translations, using examples from Genshin Impact, League of Legends, and World of Warcraft. It shows how translations can convey cultural meanings and enhance the player experience. It also introduces Glodom, a Global Top 100 Language Service Provider. Glodom has over 300 employees, serves 40+ countries, supports 150+ languages, and partners with well-known game firms.
In the global game industry, precise translation is crucial. This article analyzes the difficulties and impacts of improper game translations via examples. Problems such as polysemy, cultural controversies, ambiguous translations, and errors in key gameplay terms can harm the game's reputation and player experience. Glodom, a top 100 language service provider, has rich game localization experience, helping games succeed globally.
This article details the FDA's Investigational New Drug (IND) application process. It includes the three IND types and the necessary information in animal studies, manufacturing, and clinical aspects. After submission, there's a 30-day safety review. It also highlights the challenges of pharma globalization and the significance of language services.
On December 26th, 2024, the "2025 Overall Pharmaceutical CMC Research Strategy National Tour Salon - API Overseas Expansion Strategy Series" event in Nanjing concluded successfully. Hosted by MilestonePharma and co-organized by Glodom Technology Co., Ltd., it combined offline and online formats, attracting industry experts and enterprises. They discussed CMC strategies, API overseas expansion, and explored new paths for the Chinese pharmaceutical industry.
